Connor, Clark & Lunn Investment Management Ltd. Arrowhead Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023
SELL
$28.0 - $40.56 $826,084 - $1.2 Million
-29,503 Reduced 62.98%
17,340 $703,000
Q3 2022

Nov 10, 2022
SELL
$29.63 - $48.31 $1.18 Million - $1.93 Million
-39,950 Reduced 46.03%
46,843 $1.55 Million
Q2 2022

Aug 05, 2022
BUY
$27.79 - $50.61 $564,665 - $1.03 Million
20,319 Added 30.57%
86,793 $3.06 Million
Q1 2022

May 12, 2022
BUY
$39.62 - $69.97 $1.37 Million - $2.42 Million
34,596 Added 108.53%
66,474 $3.06 Million
Q4 2021

Feb 10, 2022
SELL
$58.09 - $82.51 $2 Million - $2.84 Million
-34,465 Reduced 51.95%
31,878 $2.11 Million
Q3 2021

Nov 12, 2021
BUY
$58.38 - $84.96 $1.83 Million - $2.67 Million
31,373 Added 89.71%
66,343 $4.14 Million
Q2 2021

Aug 12, 2021
BUY
$62.15 - $90.32 $2.17 Million - $3.16 Million
34,970 New
34,970 $2.9 Million
Q3 2017

Nov 14, 2017
SELL
$1.69 - $4.33 $165,408 - $423,798
-97,875 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
97,875
97,875 $159,000

Others Institutions Holding ARWR

# of Institutions
294
Shares Held
90.8M
Call Options Held
155K
Put Options Held
426K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.01B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email